Combined treatment for pain from bone metastases in patients with prostate cancer.
- Author:
Xiaomin REN
1
;
Jun YING
;
Dehong YAO
;
Chuanyang YE
;
Yueqing JIANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Androgen Antagonists; therapeutic use; Bone Neoplasms; physiopathology; secondary; therapy; Combined Modality Therapy; Humans; Male; Middle Aged; Pain, Intractable; therapy; Prostatic Neoplasms; therapy; Strontium; therapeutic use
- From: National Journal of Andrology 2004;10(3):188-190
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effects of combined treatment of hormone therapy with strontium-89 for pain from bone metastases in patients with prostate cancer.
METHODSSixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy.
RESULTSThe pain was relieved. Relief occurred in 75.6% of the patients for 3 months, 80.5% for 6 months and 63.4% for 9 months.
CONCLUSIONHormone therapy enhances the effect of 89Sr without obvious toxicity. The combined treatment not only significantly raises pain palliation, prolongs pain-free survival, but improves the patients life quality.
